major depressive disorder articles & resources on Made-in-China.com

Patients with Depression Have Areas of Reduced Cortical Thickness

Jan 23, 2014

Patients with depression have areas of reduced cortical thickness, with clear distinctions between those with bipolar disorder and major depressive disorder (MDD), report US researchers. "Cortical thickness may prove to be a useful tool ...

Tags: Health, Medicine

Patients with MDD Increased Use of Maladaptive and Decreased Use of Adaptive ER Strategies

Jan 16, 2014

By Lucy Piper, Senior medwireNews Reporter Patients with bipolar disorder and major depressive disorder (MDD) have increased use of maladaptive and decreased use of adaptive emotion regulation (ER) strategies, researchers report. ...

Tags: emotion regulation, Larissa Wolkenstein, University of Tübingen

BBRF Has Announced The Latest Recipients of Its Narsad Distinguished Investigator Grants

Nov 12, 2013

The Brain & Behavior Research Foundation (BBRF) (formerly known as NARSAD, the National Alliance for Research on Schizophrenia and Depression), under the direction of president and CEO Dr Jeffrey Borenstein, has announced the latest ...

Tags: Narsad, BBRF, investigator, award

Mylan Has Obtained FDA Approval for sANDA for GSK's WELLBUTRIN XL

Aug 26, 2013

Mylan has obtained FDA approval for its supplemental abbreviated new drug application (sANDA) for the generic version of GSK's WELLBUTRIN XL, bupropion hydrochloride extended-release tablets USP (XL), 300mg. Bioequivalence study results ...

Tags: FDA Approval, drug application

Naurex Has Announced The Issuance of New US Patent for Partial Agonist

Aug 2, 2013

Naurex has announced the issuance of new US patent for selective NMDA receptor partial agonist, GLYX-13, covering methods of treating major depressive disorder through 2030. In a Phase II trial, GLYX-13 demonstrated considerable safety, ...

Tags: Naurex, GLYX-13

FDA Acceptance of Vortioxetine New Drug Application Filing for Major Depressive disorder

Dec 14, 2012

Takeda Global Research & Development Center and Lundbeck have announced the FDA acceptance of vortioxetine new drug application (NDA) filing for major depressive disorder. The companies have also announced the proposal of Brintellix as ...

Tags: FDA, new drug application, NDA

Mylan Has Been Sued Jointly by Pfizer,Wyeth Pharmaceutical,Wyeth LLC and PF Prism

Dec 7, 2012

Mylan has been sued jointly by Pfizer,Wyeth Pharmaceutical,Wyeth LLC and PF Prism regarding the filing of an abbreviated new drug application (ANDA) with the US food and drug administration (FDA) for desvenlafaxine succinate ...

Tags: Mylan, desvenlafaxine succinate extended-release tablets, MDD

H. Lundbeck Have Submitted a New Drug Application

Dec 5, 2012

Takeda Pharmaceutical Company and H. Lundbeck have submitted a new drug application (NDA) to the FDA for vortioxetine (Lu AA21004), an investigational drug for the treatment of major depressive disorder (MDD). Vortioxetine is under ...

Tags: Takeda Pharmaceutical Company, major depressive disorder, MDD

Nectid Has Initiated Clinical Development of Agomelatine for Autism and Pain Indications

Nov 29, 2012

Nectid, a drug discovery company, has initiated clinical development of agomelatine for autism and pain indications in the US. Agomelatine, a melatonergic agonist (MT1 and MT2 receptors) and 5-HT2C antagonist, is approved for the ...

Tags: agomelatine, Nectid, major depressive disorder

Edgemont Pharmaceuticals Launched a Formulation Dose of Bupropion Extended-Release Tablets

Nov 29, 2012

Edgemont Pharmaceuticals has launched a new formulation dose of bupropion extended-release tablets in a strength of 450mg dose. The Forfivo XL, which the company claims, is the only available 450mg dose of an extended-release bupropion ...

Tags: bupropion extended-release tablets, bupropion product

CE Mark Has Been Won by Neurosigma External Nerve Stimulation System

Sep 7, 2012

NeuroSigma has obtained CE mark approval for its external Trigeminal Nerve Stimulation (eTNS) system, Monarch, designed for the treatment of epilepsy and major depressive disorder in adults and children of 9 years and older. The eTNS ...

Tags: NeuroSigma, eTNS, FDA

Eli Lilly Meets FDA Requirements for Pediatric Exclusivity for Cymbalta

Jul 9, 2012

Eli Lilly and Company has met the United States Food and Drug Administration (FDA) requirements for pediatric exclusivity for Cymbalta (duloxetine HCl), which is available in 20-mg, 30-mg, and 60-mg capsules. As part of the approval, ...

Tags: Eli Lilly, FDA, Cymbalta

major depressive disorder

Related Products